In diabetic mice, giving the peptide humanin for two weeks lowered several proteins linked to nerve pain and helped nerve cells stay alive, likely by turning on a JAK2/STAT3 signaling pathway. The study was done in mice and cells, not people, so it’s an early hint rather than a ready‑to‑use treatment.

This study investigates the impact of chronic humanin (HN) treatment on pain-related markers (NMDA, substance P, TRPV1, and IL-1&#x3b2;) in diabetic mice's dorsal root ganglia (DRG). Additionally, we assess the effects of HN on cellular viability in DRG neurons. <i>In vivo</i> experiments involved 15&#xa0;days of HN administration (4&#x2009;mg/kg) to diabetic mice (<i>n</i>&#xa0;=&#xa0;10). Protein levels of NMDA, IL-1&#x3b2;, TRPV1, and substance P were measured in diabetic DRG. <i>In vitro</i> experiments explored HN's impact on apoptosis and cellular viability, focusing on the JAK2/STAT3 pathway. Humanin significantly reduced the elevated expression of NMDA, IL-1&#x3b2;, TRPV1, and substance P induced by diabetes (<i>p</i>&#xa0;&lt;&#xa0;.05). Furthermore, HN treatment increased cellular viability in DRG neurons through JAK2/STAT3 pathway activation (<i>p</i>&#xa0;&lt;&#xa0;.05). These findings highlight the significance of understanding mitochondrial function and pain markers, as well as apoptosis in diabetes. The study provides insights for managing the condition and its complications.